Why most peptide evidence is in animals, and how to read it

Of 367 therapies tracked across 122 reviews, about half ever reached a human study and only 5% reached regulatory approval — and for most peptides sold online, the strongest evidence sits in animals rather than people [1]. That gap is not a verdict on peptides; it is what a field looks like when nobody can own the result. A rodent finding is a reason to run a human trial, not a substitute for one. This guide explains why the gap is so wide and gives you a quick way to read any peptide abstract.

Why so much of the evidence is animal work

Animal studies are cheap, quick and easy to publish compared with human trials. A university lab can inject a peptide into 40 rats, measure a tendon or a scar, and write it up within a year. A properly run human trial needs manufacturing to medicine standards, safety testing, ethics approval, a regulator's sign-off, and years of recruitment and follow-up. Somebody has to pay for all of that, and it's usually a company that expects to own and sell the result.

Many of the peptides people buy online have no such company behind them, or had one that stopped. So the literature stalls at the stage that's affordable: dozens of rodent papers, often from one or two groups, and no trial. That's a gap in the evidence, not a hidden vote of confidence.

How often animal results carry over

Meta-researchers have tried to put numbers on this. Three studies give a fair picture.

The 2024 umbrella review adds a detail worth knowing. When a therapy did reach human studies, positive animal results and positive human results agreed 86% of the time, which the authors read as translation delivering more often than its reputation suggests [1]. Their timeline still shows the scale of the journey: it took a median of 10 years from animal study to approval, and 95% of therapies never got there [1]. A promising rodent paper is the start of a long road.

Drugs that make it into people still fail most of the time. An analysis of industry data from 2003 to 2011 found that only around one in ten drugs entering phase 1 trials went on to approval [10].

Why rodent results mislead

The biology differs

Mice aren't small humans. A large genomic study compared blood gene responses in people after trauma, burns and sepsis with the matching mouse models. The human conditions looked strikingly similar to one another; the mouse models barely matched the human responses at all, with correlations close to random [7]. For anything framed as “anti-inflammatory” or “immune-modulating”, that's a real limit.

Rodent wounds heal differently

This matters for the healing and recovery peptides that dominate online marketing. Mice and rats have a thin muscle layer under the skin, the panniculus carnosus, that pulls wound edges together, so their skin wounds close largely by contraction, whereas human wounds rely more on growing new tissue to fill the gap [8]. Mouse skin also differs in thickness, hair-follicle density and immune make-up. A reviewer of the field put it plainly: no animal model fully predicts clinical outcomes in skin healing [8]. Tendon, gut and muscle injury models have their own versions of this problem, because the injury is induced in a young, healthy animal on a set schedule.

Doses don't scale by body weight

Small animals burn through drugs faster, so doses in mg/kg don't transfer directly. The standard method, used by regulators to pick safe starting doses, scales by body surface area. For rats, you divide the mg/kg dose by about 6.2 to get a human-equivalent mg/kg dose; for mice, the factor is about 12.3 [9]. For first-in-human trials, regulators then divide by a further safety factor, typically 10 [9].

That conversion is a starting point for safety, not a promise of effect. It says nothing about whether a peptide survives digestion, how long it lasts in human blood, or whether it reaches the target tissue. Forum dosing charts that multiply a rat's micrograms per kilogram by a person's weight are doing the sum wrong and answering the wrong question.

Many animal studies are weakly designed

A survey of 271 animal studies from publicly funded UK and US institutions found that 87% didn't use randomisation to assign animals to groups and 86% didn't blind the people measuring the outcome [6]. Only 59% even stated the study's aim along with the number and characteristics of the animals used [6]. Without those two safeguards, results lean towards what the researchers hoped to see.

Negative results often go unpublished

In animal stroke research, only 2% of 525 publications reported no significant effect on the main outcome. Statistical adjustment for the missing studies suggested publication bias inflated the reported benefit by about a third [5]. Stroke is a well-studied case; there's no reason to think peptide research is cleaner.

Sometimes animals point the wrong way

A systematic comparison found cases where animal and human results flatly disagreed [4]. Corticosteroids helped in animal models of head injury but not in the human trial. The stroke drug tirilazad shrank brain damage by 29% in animals and was linked to worse outcomes in patients [4].

How to read a peptide abstract in two minutes

You don't need the full paper to triage a study. The abstract usually answers these questions, and the answers tell you how much weight it can carry.

Two phrases deserve extra suspicion. “Trend towards” means the result wasn't statistically significant. And “improved significantly from baseline” in a controlled trial may hide the fact that the control group improved too; look for a comparison between groups.

A reasonable way to hold animal evidence

Treat a single rodent study as a question. Treat several consistent rodent studies from independent labs as a good question. Treat a small human trial as the first real clue about people, and a replicated, blinded, adequately sized human trial as evidence. On this site we label every article with the strongest kind of evidence it rests on for exactly this reason, and we name the species in the same sentence as the result.

What is still open

• Which animal models, if any, reliably predict human results for peptides specifically; the meta-research above covers drugs and therapies in general.
• How much unpublished negative peptide research exists.
• Whether newer approaches (human organoids, tissue chips) will close the gap; they're promising but largely unvalidated for predicting treatment effects.

What this means

Peptides are under-researched because nobody can own them, not because they failed. A molecule that occurs naturally in the body, or that any capable lab can synthesise, cannot be held the way a company holds a novel drug: the firm that funds a human trial needs to expect that it will own and sell the result. That is the whole economics of the field. Somebody has to pay for manufacturing to medicine standards, safety testing, ethics approval, a regulator's sign-off and years of recruitment, and most peptides sold online have no company behind them at all, or had one that stopped. So the literature stalls where it is affordable — dozens of rodent papers, often from one or two groups, and no trial. That is a gap in the evidence created by incentives, not a quiet signal that the compounds don't work.

We therefore read the missing human trials as a statement about who paid, not about what peptides do in the body. The 5% approval figure that opens this article is real, and it describes the whole field of animal-tested therapies; it is a description of the road, not a discovery about any one molecule. Most of what you will find on a given peptide sits in animal models, and a reader can hold that honestly — a rodent result is a hypothesis waiting for a human test — without treating it as a refutation.

This is the position this site takes, and you are free to disagree with it. If you think an untested peptide should be treated as hazardous until a human trial clears it, that is a coherent view, and the checklist on this page is how you would enforce it. We take the other side: the fair label for most peptides is under-studied, and under-studied is not a synonym for discredited. Labelling every article with the strongest grade of evidence it rests on, and naming the species in the same sentence as the result, is how we try to make that position checkable rather than rhetorical.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.